Obsidian Therapeutics (NASDAQ:OBX) Stock Has Average Target Price of $39.00 According to Analysts
by Amy Steele · The Cerbat GemShares of Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) have been given an average rating of “Moderate Buy” by the seven research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $39.00.
A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Obsidian Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, October 25th. Zacks Research upgraded shares of Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. Leerink Partners assumed coverage on Obsidian Therapeutics in a research report on Tuesday, September 22nd. They set an “outperform” rating and a $32.00 price objective on the stock. Weiss Ratings assumed coverage on Obsidian Therapeutics in a report on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Finally, Lifesci Capital initiated coverage on Obsidian Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 target price for the company.
Obsidian Therapeutics Price Performance
NASDAQ:OBX opened at $14.43 on Thursday. The stock has a 50-day moving average of $15.18. Obsidian Therapeutics has a 12 month low of $11.52 and a 12 month high of $49.97.
About Obsidian Therapeutics
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.
Featured Stories
- Five stocks we like better than Obsidian Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid